China Resources Double-Crane Pharmaceutical Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | China Resources Shuanghe Pharmaceutical Co., Ltd. has a glorious history of 83 years, founded in 1939 as a military pharmaceutical factory. It was originally born in the Taihang Mountain Revolutionary Base and is known as Lihua Pharmaceutical Factory externally; In 1949, he moved to Beijing with the army and later changed his name to Beijing Pharmaceutical Factory. He developed into a large state-owned chemical and pharmaceutical comprehensive preparation enterprise, laying the foundation for Beijing's modern chemical and pharmaceutical industry; In 1997, it was listed on the Shanghai Stock Exchange and expanded into a cross regional group based in Beijing and radiating across the country through expansion; In 2010, it entered the Fortune 500 company China Resources Group and is now one of the business units in the big health field of China Resources Group. The main business covers new drug research and development, formulation production, drug sales, pharmaceutical equipment, and raw material drug production. It has a rich product line, high-quality product quality and cost control, strong channel and terminal coverage and management capabilities, good brand advantages and international advantages, a vibrant team, and a deep corporate culture. Its economic strength, competitive vitality, and sustainable development ability are among the top domestic pharmaceutical companies. In 2021, the main business revenue was 9.03 billion yuan, and the net profit (attributable to the parent company) was 940 million yuan. The company actively lays out four major business platforms: generic medicine business, infusion business, differentiated medicine business, and innovative medicine business, deeply delving into the fields of chronic diseases, infusion, pediatrics, nephrology, and psychiatry/neurology. It has an annual sales revenue of over 100 million yuan for 19 key products, including No. 0, Guanshuang, Yashida, Suiyue, Tangshiping, BFS infusion, Kelisau, peritoneal dialysis fluid, and magnesium valproate sustained-release tablets. It owns well-known Chinese trademarks such as "Shuanghe and Tu", "SECCO", and "Xiangzhong", and has won multiple honors such as "Top 100 Chinese Chemical and Pharmaceutical Enterprises", "Top 100 Comprehensive Strength of Chinese Chemical and Pharmaceutical Industry Enterprises", "High tech Enterprise", and "Quality Management Award of Beijing Municipal People's Government". The company has good research and development capabilities, vigorously promotes product acquisition, builds multiple production technology platforms, and actively cooperates with domestic and foreign universities, research and development institutions, and pharmaceutical enterprises to provide more product choices for the market; We have first-class production and manufacturing capabilities in China, with 20 production bases located in 14 provinces and cities in North China, Northwest China, Central China, South China, and other regions. We have established an advanced production management system, and our quality management is in line with international first-class standards, providing safe and effective health support for millions of patients; The sales network covers 33 provinces, municipalities, autonomous regions, and special administrative regions across the country, and has a strong influence in the markets of North China, Jiangsu, Zhejiang, and infusion base areas. Some raw materials and preparation products are exported to more than 30 countries in the international market. Through rich product support, thoughtful marketing services, good terminal control capabilities, and professional marketing teams, we work hand in hand with customers to achieve a win-win situation. In the future, CR Shuanghe will continue to accelerate innovation transformation and quality development, committed to becoming a trusted and innovation driven world-class pharmaceutical enterprise, and making greater contributions to industry development and public health. |
| Headquarter | Beijing |
| Establish Date | 5/16/1997 |
| Listed Code | 600062.SH |
| Listed Date | 5/22/1997 |
| Chairman | Lu Wenchao. |
| CEO | Lu Wenchao. |
| Website | www.dcpc.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
